Fujirebio Inc.

Unitika Ltd.

Fujirebio Kabushiki Kaisha

Tetsuaki Yamaura

Hiroshi Ikawa

Noriko Kase

Akiyoshi Kadoiri

Yasuko Konagai

Eiko Mori

Masakatsu Matsumoto

Nobuko Watanabe

Yasuo Sekine

Akihiro Sekine

Yasushi Higashide

Misao Aoyama

Yoshikazu Isowa

Hajime Matsumoto

Yoshiharu Nakashima

Hisako Kobayashi

Noriaki Kashiwaba

Michiyo Hizuka

Miwa Ishihara

Hiroshi Nakajima

Masato Nishimura

Akihiko Hosoda

Masafumi Kitakaze

Nobuhiko Hirakawa

Masashi Nishikawa

Teruo Kutsuma

Hisako Harada

Nobuhiro Hirakawa

Kunihiro Okamura

Niro Inaba

Yasuko Emoto

Eri Kojima

Takenobu Kamada

Masatsugu Hori

Disclosed is an azapeptide derivative represented by the formula (I): ##STR1## wherein A represents a direct bond, an .alpha.-amino acid or a residue of a dipeptide; R.sup.1 represents a hydrogen atom or a protective group for a terminal amino group; R.sup.2 represents a phenyl group or a phenyl group substituted by one or two substituents selected from the group consisting of a lower alkyl group, halogen atom, hydroxyl group which may be protected, nitro group, amino group which may be protected and perhalo lower alkyl group; and R.sup.3 represents a hydroxyl group or a protective group for a terminal carboxyl group, and a salt thereof, and an agent for curing nervous inflammation of respiratory apparatus, asthma and bronchospasm comprising the azapeptide derivative represented by the formula (I) or a salt thereof as an active ingredient.

Azapeptide derivative

1,4-dihydropyridine derivatives and optically active 1,4-dihydropyridine derivatives with the following formula, having vasodilating activity based on calcium antagonism, and PAF antaognism, and methods of producing the same are disclosed: ##STR1## wherein (*) indicates a chiral center in the case of the optically active 1,4-dihydropyridine derivatives.

1,4-dihydropyridine derivatives and methods of producing the same

Disclosed is an azapeptide derivative represented by the formula (I): ##STR1## wherein A represents a direct bond, an .alpha.-amino acid or a residue of a dipeptide; R.sup.1 represents a hydrogen atom or a protective group for a terminal amino group;

1,4-dihydropyridine derivatives and optically active 1,4-dihydropyridine derivatives with the following formula, having vasodilating activity based on calcium antagonism, and PAF antagonism, and methods of producing the same are disclosed: ##STR1## wherein (*) indicates a chiral center in the case of the optically active 1,4-dihydropyridine derivatives.

1, 4-Dihydropyridine derivatives and methods of producing the same

An agent for curing ischemic myocardial disease which contains an effective amount of diadenosine 5',5''-p.sup.1,p.sup.4 -tetraphosphate (Ap4A) of formula (I): ##STR1## or a pharmaceutically-acceptable salt thereof.

Agent for curing ischemic myocardial disease

A 4-fluorobiphenyl derivative of formula (I), which is useful as a cholesterol lowering agent or a lipid lowering agent because of its strong inhibitory effect on HMG-CoA reductase), and which is also useful as an intermediate for producing the above-mentioned cholesterol lowering agent or lipid lowering agent: ##STR1## wherein A is a .omega.-oxycarbonyldihydroxybutyl group, a tetrahydropyranyl group, a .omega.-oxycarbonyl-3-oxobutyl group, a formyl group, or a cyano group; R.sup.1 is a halogen atom, an alkyl group, or a group represented by R.sup.5 O--, wherein R.sup.5 is a hydrogen atom, or an alkyl group; R.sup.2 is a hydrogen atom, an alkyl group; R.sup.3 is a hydrogen atom, or an alkyl group; R.sup.5 and R.sup.2 may form a five-membered ring or a six-membered ring in combination with the oxygen atoms to which R.sup.5 and R.sup.2 are respectively bonded, and R.sup.5 and R.sup.3 may form a five-membered ring or a six-membered ring in combination with the oxygen atom to which R.sup.5 is bonded.

4-fluorobiphenyl derivatives

A 4-fluorobiphenyl derivative of formula (I): ##STR1## wherein A is a .omega.-oxycarbonyldihydroxybutyl group of formula (II): ##STR2## wherein R.sup.2 is a hydrogen atom, an alkyl group, an alkaline metal or an alkaline earth metal; a tetrahydropyranyl group of formula (III): ##STR3## or a .omega.-oxycarbonyl-3-oxobutyl group of formula (IV): ##STR4## wherein R.sup.3 is an alkyl group; R.sup.1 is an alkyl group. This 4-fluorobiphenyl derivative is useful as an effective component for a cholesterol or lipid lowering agent.

1,4-dihydropyridine derivatives

A naphthoic acid derivative represented by the following general formula or a salt thereof: ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are each independently a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group, a lower alkoxy group, a lower alkanoyloxy group, a hydroxy-lower alkyl group, a lower alkoxy-lower alkyl group, a lower alkanoyloxy-lower alkyl group or an aralkyloxy group;

Naphthoic acid derivative

4-hydroxytetrahydropyran-2-one and 3,5-Dihydroxyheptanoic acid derivatives of formula (I) and formula (II) have an inhibition effect on HMG-CoA reductase, a cholesterol value reduction effect, and an antioxidation function, thus serving as cholesterol reducing agent or lipid reducing agents: ##STR1## wherein R.sup.1 represents hydrogen, a nitro group, or -N(R.sup.4)R.sup.5 in which R.sup.4 and R.sup.5 each represent an alkyl group, an alkenyl group, an aryl group, an aralkyl group; an acyl group, an aroyl group, a carbamoyl group, or a thiocarbamoyl group, and R.sup.4 and R.sup.5 may be combined to form a cyclic amino group; and R.sup.2 and R.sup.3 each represent hydrogen or an alkyl group; and R.sup.6 represents hydrogen, an alkyl group, an alkali metal, or an alkaline earth metal.

3,5-dihydroxyheptanoic acid derivatives

The present invention relates to a pharmaceutical composition for treating a heart disease which comprises a therapeutically effective amount of diadenosine 5',5''-P.sup.1, P.sup.4 -tetraphosphate as an active ingredient in admixture with a pharmaceutically acceptable carrier or diluent. The pharmaceutical composition is particularly characterized by having antiarrhythmic and coronary vasodilative activities. The present invention also relates to a method for treating a subject having a heart disease or particularly arrhythmia, which comprises administering to the subject an effective amount of the pharmaceutical composition.

Treatment of arrhythmia by administration of Ap.sub.4 A

A compound represented by the following formula or a salt thereof ##STR1## wherein each of R.sub.1 and R.sub.2 represents a lower alkyl group, or R.sub.1 and R.sub.2, together with the nitrogen atom to which they are bonded, may form a substituted or unsubstituted, saturated or partially unsaturated 4- to 8-membered heterocyclic group which may contain a hetero atom selected from N, O and S, Y represents a group of the formula --CH.sub.2 --CH.sub.2 -- or --CH.dbd.CH--, and n is 0, 1 or 2. This compound is useful as anti-peptic ulcer agent.

4-aminomethyl-pyridyl-2-oxy derivatives having anti-ulcer activity

Alkylamide derivatives having the formula, These compounds have a strong antiulcer action depend on histamine H.sub.2 -receptor antagonistic action and a cytoprotective action upon gastric mucous membrance.

Alkylamide derivatives with H.sub.2 -receptor antagonistic and

Growing community of inventors

Tokyo, Japan

Tetsuaki Yamaura